135 related articles for article (PubMed ID: 19856102)
1. Highly purified eicosapentaenoic acid ethyl ester prevents development of steatosis and hepatic fibrosis in rats.
Kajikawa S; Harada T; Kawashima A; Imada K; Mizuguchi K
Dig Dis Sci; 2010 Mar; 55(3):631-41. PubMed ID: 19856102
[TBL] [Abstract][Full Text] [Related]
2. Eicosapentaenoic acid attenuates progression of hepatic fibrosis with inhibition of reactive oxygen species production in rats fed methionine- and choline-deficient diet.
Kajikawa S; Imada K; Takeuchi T; Shimizu Y; Kawashima A; Harada T; Mizuguchi K
Dig Dis Sci; 2011 Apr; 56(4):1065-74. PubMed ID: 20848203
[TBL] [Abstract][Full Text] [Related]
3. Pigment Epithelium-Derived Factor (PEDF) Prevents Hepatic Fat Storage, Inflammation, and Fibrosis in Dietary Steatohepatitis of Mice.
Yoshida T; Akiba J; Matsui T; Nakamura K; Hisamoto T; Abe M; Ikezono Y; Wada F; Iwamoto H; Nakamura T; Koga H; Yamagishi SI; Torimura T
Dig Dis Sci; 2017 Jun; 62(6):1527-1536. PubMed ID: 28365916
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin attenuates methionine/choline-deficient diet-induced steatohepatitis.
Jung YA; Choi YK; Jung GS; Seo HY; Kim HS; Jang BK; Kim JG; Lee IK; Kim MK; Park KG
Diabetes Res Clin Pract; 2014 Jul; 105(1):47-57. PubMed ID: 24842243
[TBL] [Abstract][Full Text] [Related]
5. The modulation of hepatic adenosine triphosphate and inflammation by eicosapentaenoic acid during severe fibrotic progression in the SHRSP5/Dmcr rat model.
Jia X; Naito H; Yetti H; Tamada H; Kitamori K; Hayashi Y; Yamagishi N; Wang D; Yanagiba Y; Ito Y; Wang J; Tanaka N; Ikeda K; Yamori Y; Nakajima T
Life Sci; 2012 Jun; 90(23-24):934-43. PubMed ID: 22569299
[TBL] [Abstract][Full Text] [Related]
6. Rosiglitazone prevents nutritional fibrosis and steatohepatitis in mice.
Nan YM; Fu N; Wu WJ; Liang BL; Wang RQ; Zhao SX; Zhao JM; Yu J
Scand J Gastroenterol; 2009; 44(3):358-65. PubMed ID: 18991162
[TBL] [Abstract][Full Text] [Related]
7. No significant effects of ethyl-eicosapentanoic acid on histologic features of nonalcoholic steatohepatitis in a phase 2 trial.
Sanyal AJ; Abdelmalek MF; Suzuki A; Cummings OW; Chojkier M;
Gastroenterology; 2014 Aug; 147(2):377-84.e1. PubMed ID: 24818764
[TBL] [Abstract][Full Text] [Related]
8. Polaprezinc attenuates liver fibrosis in a mouse model of non-alcoholic steatohepatitis.
Sugino H; Kumagai N; Watanabe S; Toda K; Takeuchi O; Tsunematsu S; Morinaga S; Tsuchimoto K
J Gastroenterol Hepatol; 2008 Dec; 23(12):1909-16. PubMed ID: 18422963
[TBL] [Abstract][Full Text] [Related]
9. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.
Yamaguchi K; Yang L; McCall S; Huang J; Yu XX; Pandey SK; Bhanot S; Monia BP; Li YX; Diehl AM
Hepatology; 2007 Jun; 45(6):1366-74. PubMed ID: 17476695
[TBL] [Abstract][Full Text] [Related]
10. Tranilast, an antifibrogenic agent, ameliorates a dietary rat model of nonalcoholic steatohepatitis.
Uno M; Kurita S; Misu H; Ando H; Ota T; Matsuzawa-Nagata N; Kita Y; Nabemoto S; Akahori H; Zen Y; Nakanuma Y; Kaneko S; Takamura T
Hepatology; 2008 Jul; 48(1):109-18. PubMed ID: 18571789
[TBL] [Abstract][Full Text] [Related]
11. Oxidative stress, KLF6 and transforming growth factor-beta up-regulation differentiate non-alcoholic steatohepatitis progressing to fibrosis from uncomplicated steatosis in rats.
Stärkel P; Sempoux C; Leclercq I; Herin M; Deby C; Desager JP; Horsmans Y
J Hepatol; 2003 Oct; 39(4):538-46. PubMed ID: 12971963
[TBL] [Abstract][Full Text] [Related]
12. Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis.
Depner CM; Philbrick KA; Jump DB
J Nutr; 2013 Mar; 143(3):315-23. PubMed ID: 23303872
[TBL] [Abstract][Full Text] [Related]
13. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice.
Velayudham A; Dolganiuc A; Ellis M; Petrasek J; Kodys K; Mandrekar P; Szabo G
Hepatology; 2009 Mar; 49(3):989-97. PubMed ID: 19115316
[TBL] [Abstract][Full Text] [Related]
14. Highly purified eicosapentaenoic acid prevents the progression of hepatic steatosis by repressing monounsaturated fatty acid synthesis in high-fat/high-sucrose diet-fed mice.
Kajikawa S; Harada T; Kawashima A; Imada K; Mizuguchi K
Prostaglandins Leukot Essent Fatty Acids; 2009 Apr; 80(4):229-38. PubMed ID: 19328666
[TBL] [Abstract][Full Text] [Related]
15. Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats.
Luo ZL; Tang LJ; Wang T; Dai RW; Ren JD; Cheng L; Xiang K; Tian FZ
J Gastroenterol Hepatol; 2014 Jan; 29(1):215-22. PubMed ID: 24117897
[TBL] [Abstract][Full Text] [Related]
16. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue.
Kudo H; Yata Y; Takahara T; Kawai K; Nakayama Y; Kanayama M; Oya T; Morita S; Sasahara M; Mann DA; Sugiyama T
Liver Int; 2009 Aug; 29(7):988-96. PubMed ID: 19386026
[TBL] [Abstract][Full Text] [Related]
17. Pan-caspase inhibitor VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Witek RP; Stone WC; Karaca FG; Syn WK; Pereira TA; Agboola KM; Omenetti A; Jung Y; Teaberry V; Choi SS; Guy CD; Pollard J; Charlton P; Diehl AM
Hepatology; 2009 Nov; 50(5):1421-30. PubMed ID: 19676126
[TBL] [Abstract][Full Text] [Related]
18. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis.
Tanaka N; Sano K; Horiuchi A; Tanaka E; Kiyosawa K; Aoyama T
J Clin Gastroenterol; 2008 Apr; 42(4):413-8. PubMed ID: 18277895
[TBL] [Abstract][Full Text] [Related]
19. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet.
Nagasawa T; Inada Y; Nakano S; Tamura T; Takahashi T; Maruyama K; Yamazaki Y; Kuroda J; Shibata N
Eur J Pharmacol; 2006 Apr; 536(1-2):182-91. PubMed ID: 16574099
[TBL] [Abstract][Full Text] [Related]
20. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice.
Ip E; Farrell G; Hall P; Robertson G; Leclercq I
Hepatology; 2004 May; 39(5):1286-96. PubMed ID: 15122757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
